| Literature DB >> 11967146 |
Jonathan D Adachi1, George Ioannidis, Wojciech P Olszynski, Jacques P Brown, David A Hanley, Rolf J Sebaldt, Annie Petrie, Alan Tenenhouse, Gregory F Stephenson, Alexandra Papaioannou, Gordon H Guyatt, Charlie H Goldsmith.
Abstract
BACKGROUND: Little empirical research has examined the multiple consequences of osteoporosis on quality of life.Entities:
Year: 2002 PMID: 11967146 PMCID: PMC107028 DOI: 10.1186/1471-2474-3-11
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Patient Characteristicsa
| Incident VF Group (I) | Incident Non-VF Group (II) | No Incident Fracture Group (III) | |
| Number of patients | 47 | 149 | 1813 |
| Age-mean (SD) | 72.5 (8.6) | 68.5 (9.6) | 65.3 (8.8) |
| Weight-kg | 62.2 (12.3) | 64.9 (12.6) | 64.8 (12.8) |
| Height – cm | 154.4 (6.7) | 156.9 (6.6) | 157.4 (8.3) |
| Dietary Ca-g/d | 0.8 (0.4) | 0.6 (0.3) | 0.6 (0.3) |
| Exercise-hours/week | 1.8 (2.6) | 2.8 (3.4) | 2.9 (3.5) |
| Race-# (%) | |||
| Caucasian | 10 (21.3) | 29 (19.5) | 473 (26.1) |
| Otherb | 1 (2.1) | 0 (0) | 26 (1.4) |
| Unknown | 36 (76.6) | 120 (80.5) | 1314 (72.5) |
| BMD-mean (SD) | |||
| LS-g/cm2 | 0.876 (0.131) | 0.941 (0.169) | 0.954 (0.148) |
| FN-g/cm2 | 0.687 (0.101) | 0.715 (0.120) | 0.734 (0.109) |
| Prevalent fractures – # (%) | |||
| VF | 24 (51.1) | 38 (25.5) | 326 (18.0) |
| Non-VF | 33 (70.2) | 98 (66.8) | 828 (45.7) |
| Multiple VF (>1) | 16 (34.0) | 17 (11.4) | 194 (10.7) |
| Multiple Non-VF (>1) | 22 (46.8) | 59 (39.6) | 467 (25.8) |
| Concomitant diseases-# (%) | |||
| Heart attack | 7 (14.9) | 25 (16.8) | 262 (14.5) |
| Stroke | 3 (6.4) | 3 (2.0) | 58 (3.2) |
| Cancerc | 5 (10.6) | 15 (10.0) | 162 (8.9) |
| Diabetes | 2 (4.3) | 6 (4.0) | 58 (3.2) |
| Epilepsy | 2 (4.3) | 2 (1.3) | 17 (0.9) |
| Arthritis | 25 (53.2) | 78 (52.4) | 1037 (57.2) |
| Thyroid diseased | 13 (27.7) | 36 (24.2) | 345 (19.0) |
| Medications-# (%) | |||
| Bisphosphonatese | 40 (85.1) | 109 (73.2) | 1252 (69.1) |
| Estrogen | 16 (34.0) | 50 (33.6) | 767 (42.3) |
| Other medicationsf | 4 (8.5) | 3 (2.0) | 42 (2.3) |
a VF = vertebral fracture; Ca = calcium; SD = standard deviation; BMD = bone mineral density; LS = lumbar spine; FN = femoral neck; # = number of patients; % = percent of patients within each group. b others may have included one of the following Asian, Black, Aboriginal North American, Oriental, and Middle Eastern/North African White cincludes breast, ovarian, uterine or cervical, colon cancer; and multiple myeloma. d includes hyper, hypo, nodular and other thyroid diseases. e includes alendronate or etidronate. f includes fluoride, calcitonin or raloxifene.
Unadjusted Standardized Scores of the mini-OQLQ for Patients With and Without Incident Fracturesa.
| Mini-OQLQ | Vertebral Fracture Group (I) | Non-Vertebral Fracture Group (II) | No Fracture Group (III) | ||||||
| Domains | Baseline | Follow-up | n | Baseline | Follow-up | n | Baseline | Follow-up | n |
| Total Score | 4.27 (1.83) | 3.54 (1.79) | 14 | 4.99 (1.37) | 4.64 (1.35) | 52 | 5.46 (1.43) | 5.49 (1.36) | 685 |
| Symptoms | 3.98 (1.76) | 3.26 (1.65) | 44 | 4.82 (1.62) | 4.64 (1.51) | 136 | 5.08 (1.61) | 5.07 (1.62) | 1711 |
| Physical Functioning | 3.99 (2.11) | 3.26 (1.90) | 34 | 5.14 (1.68) | 4.83 (1.72) | 102 | 5.26 (1.77) | 5.31 (1.75) | 1192 |
| Emotional Functioning | 4.16 (2.13) | 3.72 (2.27) | 45 | 5.41 (1.69) | 4.54 (1.85) | 139 | 5.65 (1.55) | 5.67 (1.49) | 1711 |
| Activities of Daily Living | 4.25 (2.12) | 3.18 (1.91) | 30 | 5.24 (1.80) | 4.89 (1.84) | 105 | 5.34 (1.81) | 5.40 (1.75) | 1260 |
| Leisure | 5.10 (2.07) | 4.31 (2.20) | 26 | 5.42 (1.84) | 5.51 (1.78) | 75 | 6.01 (1.54) | 6.02 (1.51) | 1012 |
a Only patients with both pre and post measurements were evaluated. Entries are means (standard deviation). n = sample size.
Unadjusted and Adjusted Regression Coefficient Estimates and 95% Confidence Intervals (CI) that Explain the mini-OQLQ for Patients With Incident Fractures Versus Those Without Incident Fracturesa.
| Mini-OQLQ | Vertebral Fracture Group (I) | Non-Vertebral Fracture Group (II) | ||||||
| Domains | Estimates Unadjusted CI | (n) | Adjusted Estimates CI | (n) | Unadjusted Estimates CI | (n) | Adjusted Estimates CI | (n) |
| Total Score | -0.77 | (699) | -0.86 | (673) | -0.38 | (737) | -0.47 | (711) |
| -1.22, -0.31 | -1.30, -0.43 | -0.62, -0.13 | -0.70, -0.25 | |||||
| Symptoms | -0.70 | (1755) | -0.76 | (1214) | -0.17 | (1847) | -0.25 | (1295) |
| -1.12, -0.29 | -1.23, -0.30 | -0.41, 0.07c | -0.49, -0.01 | |||||
| Physical Functioning | -0.76 | (1226) | -1.12 | (1113) | -0.35 | (1294) | -0.39 | (1181) |
| -1.20, -0.32 | -1.57, -0.67 | -0.62, -0.09 | -0.65, -0.14 | |||||
| Emotional Functioning | -0.46 | (1756) | -1.06 | (1581) | -0.90 | (1850) | -0.97 | (1669) |
| -0.85, -0.07 | -1.44, -0.68 | -1.13, -0.66 | -1.20, -0.75 | |||||
| Activities of Daily Living | -1.13 | (1290) | -1.47 | (1116) | -0.41 | (1365) | -0.47 | (1188) |
| -1.63, -0.63 | -1.97, -0.96 | -0.69, -0.14 | -0.73, -0.21 | |||||
| Leisure | -0.81 | (1038) | -0.92 | (991) | 0.08 | (1087) | -0.05 | (953) |
| -1.29, -0.32 | -1.37, -0.47 | -0.22, 0.37c | -0.32, 0.23c | |||||
aRegression coefficient estimates and 95% CI were calculated based on differences between the incident vertebral and incident non-vertebral fracture group versus the no fracture group (reference level: no incident fracture group) between pre and post HRQL measurements. The covariates included in the multiple regression analysis were group; baseline mini-OQLQ score; group by baseline mini-OQLQ score interaction; number of years between pre and post administration of the mini-OQLQ; age; baseline height; baseline weight; change in height (post-pre); prevalent vertebral and non-vertebral fracture status; number of prevalent vertebral and non-vertebral fractures; time spent exercising (hours/week); dietary calcium intake (g/day); baseline bone mineral density of the lumbar spine and femoral neck; medications such as bisphosphonates (etidronate or alendronate), estrogen, or others (calcitonin, fluoride or raloxifene); and co-morbidities (including heart attack; stroke; breast, ovarian, cervical, uterine and colon cancer and multiple myeloma; diabetes, epilepsy, arthritis, and thyroid disease). b (n) = sample size. c indicates a non significant differences between groups (the non-vertebral fracture group (II) versus the no fracture group (III)).